Ignite Creation Date:
2025-12-24 @ 5:45 PM
Ignite Modification Date:
2026-01-06 @ 9:30 AM
Study NCT ID:
NCT00326768
Status:
COMPLETED
Last Update Posted:
2017-12-28
First Post:
2006-05-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-05
Start Date Type:
None
Primary Completion Date:
2007-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2007-08
Completion Date Type:
None
First Submit Date:
2006-05-16
First Submit QC Date:
None
Study First Post Date:
2006-05-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-12-27
Last Update Post Date:
2017-12-28
Last Update Post Date Type:
ACTUAL